The global survey revealed similar challenges for individuals with unilateral and bilateral geographic atrophy.

Bonnie An Henderson, MD, shares a few of the emerging trends in eye care she and the faculty plan to tackle at the 2025 EnVision Summit.

If approved, Glaukos states that Epioxa would be the first FDA-approved, non-invasive corneal cross-linking therapy that does not require removal of the corneal epithelium.

According to Mile Brujic, OD, FAAO, low-level light therapy (LLLT) and intense pulsed light have demonstrated tremendous benefits for his patients.

Catch up on what happened in optometry during the week of December 16-December 20.

The American Optometric Association and Association of Armed Forces and Federal Optometric Services have advocated for the legislature’s passage.

Reviewing new AMD treatments and research can help optometrists prepare for what's to come in 2025.

Optometrists reflect on their residency experiences and provide advice to current residents.

Research was based on results of a double-blinded, randomized, clinical trial performed between November 2017 and December 2022 in the strabismus clinic of Farabi Eye Hospital.

EnVision Summit optometry faculty Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.

Key takeaways from the past year that can help optometrists look ahead to 2025.

Mice with reduced levels of ERCC1-XPF in the study presented abnormal optokinetic and electroretinogram responses consistent with photoreceptor dysfunction and visual impairment.

Aurion Biotech announced that Phase 1/2 CLARA trial of AURN001 for corneal edema demonstrated significant dose-dependent efficacy, especially in the high-dose group, with favorable safety and tolerability profiles.

The University of Colorado study found that patient visits for irritation and allergies more than double during high particulate matter levels, emphasizing the need for proactive clinical strategies.

The researchers identified 940 teprotumumab-associated adverse events that included 84 hearing-related adverse events. The first was reported to the FDA in April 2020.

Bonnie An Henderson, MD, program director and cofounder of EnVision Summit, shares some background on the meeting, which takes place February 14-17, 2025 in Puerto Rico.

Optometrists weigh in on the importance of building patient loyalty.

A few optometrists share which innovations in optometry they were most excited about in 2024.

Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections.